nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CHRM3—nephrolithiasis	0.76	1	CbGaD
Paroxetine—CHRM3—ureter—nephrolithiasis	0.00896	0.391	CbGeAlD
Paroxetine—Stress—Hydrochlorothiazide—nephrolithiasis	0.00891	0.0657	CcSEcCtD
Paroxetine—Anxiety disorder—Hydrochlorothiazide—nephrolithiasis	0.00722	0.0532	CcSEcCtD
Paroxetine—Henoch-Schonlein purpura—Hydrochlorothiazide—nephrolithiasis	0.00492	0.0363	CcSEcCtD
Paroxetine—Sialoadenitis—Hydrochlorothiazide—nephrolithiasis	0.00458	0.0337	CcSEcCtD
Paroxetine—Stiffness—Hydrochlorothiazide—nephrolithiasis	0.00294	0.0217	CcSEcCtD
Paroxetine—Arrhythmia supraventricular—Hydrochlorothiazide—nephrolithiasis	0.00288	0.0212	CcSEcCtD
Paroxetine—Raised liver function tests—Hydrochlorothiazide—nephrolithiasis	0.00242	0.0178	CcSEcCtD
Paroxetine—Trauma—Hydrochlorothiazide—nephrolithiasis	0.00235	0.0173	CcSEcCtD
Paroxetine—Anorectal disorder—Hydrochlorothiazide—nephrolithiasis	0.00213	0.0157	CcSEcCtD
Paroxetine—CYP2C9—urine—nephrolithiasis	0.0021	0.0915	CbGeAlD
Paroxetine—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00199	0.0147	CcSEcCtD
Paroxetine—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.00199	0.0147	CcSEcCtD
Paroxetine—Toothache—Hydrochlorothiazide—nephrolithiasis	0.00184	0.0135	CcSEcCtD
Paroxetine—TACR1—renal system—nephrolithiasis	0.00173	0.0756	CbGeAlD
Paroxetine—HTR2A—urine—nephrolithiasis	0.00173	0.0754	CbGeAlD
Paroxetine—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.00167	0.0123	CcSEcCtD
Paroxetine—CYP2D6—urine—nephrolithiasis	0.00157	0.0687	CbGeAlD
Paroxetine—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00146	0.0108	CcSEcCtD
Paroxetine—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00918	CcSEcCtD
Paroxetine—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00124	0.00912	CcSEcCtD
Paroxetine—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.0012	0.00888	CcSEcCtD
Paroxetine—Gout—Hydrochlorothiazide—nephrolithiasis	0.0012	0.00882	CcSEcCtD
Paroxetine—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00118	0.00871	CcSEcCtD
Paroxetine—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00114	0.00839	CcSEcCtD
Paroxetine—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00823	CcSEcCtD
Paroxetine—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.0011	0.00809	CcSEcCtD
Paroxetine—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00105	0.00777	CcSEcCtD
Paroxetine—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00105	0.00773	CcSEcCtD
Paroxetine—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00102	0.00752	CcSEcCtD
Paroxetine—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00101	0.00744	CcSEcCtD
Paroxetine—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00101	0.00744	CcSEcCtD
Paroxetine—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.000995	0.00733	CcSEcCtD
Paroxetine—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.000937	0.00691	CcSEcCtD
Paroxetine—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.000933	0.00687	CcSEcCtD
Paroxetine—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.000924	0.00681	CcSEcCtD
Paroxetine—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.000924	0.00681	CcSEcCtD
Paroxetine—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.000915	0.00674	CcSEcCtD
Paroxetine—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.000907	0.00668	CcSEcCtD
Paroxetine—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.000898	0.00662	CcSEcCtD
Paroxetine—Injury—Hydrochlorothiazide—nephrolithiasis	0.000882	0.0065	CcSEcCtD
Paroxetine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.000875	0.00645	CcSEcCtD
Paroxetine—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.000863	0.00636	CcSEcCtD
Paroxetine—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00086	0.00633	CcSEcCtD
Paroxetine—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.000856	0.00631	CcSEcCtD
Paroxetine—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.000856	0.00631	CcSEcCtD
Paroxetine—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.000852	0.00628	CcSEcCtD
Paroxetine—Thirst—Hydrochlorothiazide—nephrolithiasis	0.000852	0.00628	CcSEcCtD
Paroxetine—Purpura—Hydrochlorothiazide—nephrolithiasis	0.000842	0.0062	CcSEcCtD
Paroxetine—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.000835	0.00615	CcSEcCtD
Paroxetine—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.000814	0.006	CcSEcCtD
Paroxetine—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.000811	0.00598	CcSEcCtD
Paroxetine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.000805	0.00593	CcSEcCtD
Paroxetine—Migraine—Hydrochlorothiazide—nephrolithiasis	0.000798	0.00588	CcSEcCtD
Paroxetine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.000798	0.00588	CcSEcCtD
Paroxetine—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.000783	0.00577	CcSEcCtD
Paroxetine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.000768	0.00566	CcSEcCtD
Paroxetine—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.000763	0.00562	CcSEcCtD
Paroxetine—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.000749	0.00552	CcSEcCtD
Paroxetine—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.000743	0.00548	CcSEcCtD
Paroxetine—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.000741	0.00546	CcSEcCtD
Paroxetine—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.000738	0.00544	CcSEcCtD
Paroxetine—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.000733	0.0054	CcSEcCtD
Paroxetine—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00073	0.00538	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00073	0.00538	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00073	0.00538	CcSEcCtD
Paroxetine—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.000718	0.00529	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000715	0.00527	CcSEcCtD
Paroxetine—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.000715	0.00527	CcSEcCtD
Paroxetine—CHRM3—renal system—nephrolithiasis	0.000712	0.0311	CbGeAlD
Paroxetine—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.000711	0.00873	CbGpPWpGaD
Paroxetine—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.000701	0.00517	CcSEcCtD
Paroxetine—Influenza—Hydrochlorothiazide—nephrolithiasis	0.000701	0.00517	CcSEcCtD
Paroxetine—CHRM3—kidney—nephrolithiasis	0.000688	0.03	CbGeAlD
Paroxetine—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.000687	0.00507	CcSEcCtD
Paroxetine—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.000683	0.00503	CcSEcCtD
Paroxetine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.000656	0.00483	CcSEcCtD
Paroxetine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00065	0.00798	CbGpPWpGaD
Paroxetine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.000648	0.00477	CcSEcCtD
Paroxetine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.000646	0.00476	CcSEcCtD
Paroxetine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00064	0.00472	CcSEcCtD
Paroxetine—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.000638	0.0047	CcSEcCtD
Paroxetine—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.000632	0.00466	CcSEcCtD
Paroxetine—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.000629	0.00463	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00062	0.00457	CcSEcCtD
Paroxetine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.000616	0.00454	CcSEcCtD
Paroxetine—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.000613	0.00452	CcSEcCtD
Paroxetine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.000613	0.00452	CcSEcCtD
Paroxetine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.000611	0.00751	CbGpPWpGaD
Paroxetine—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.000609	0.00449	CcSEcCtD
Paroxetine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.000608	0.00448	CcSEcCtD
Paroxetine—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.000608	0.00448	CcSEcCtD
Paroxetine—Sweating—Hydrochlorothiazide—nephrolithiasis	0.000599	0.00442	CcSEcCtD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000598	0.00734	CbGpPWpGaD
Paroxetine—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.000596	0.00439	CcSEcCtD
Paroxetine—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00059	0.00434	CcSEcCtD
Paroxetine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.000586	0.00432	CcSEcCtD
Paroxetine—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.000583	0.0043	CcSEcCtD
Paroxetine—CYP2C8—renal system—nephrolithiasis	0.000578	0.0252	CbGeAlD
Paroxetine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.000571	0.00421	CcSEcCtD
Paroxetine—CYP2B6—nephron tubule—nephrolithiasis	0.00057	0.0249	CbGeAlD
Paroxetine—CHRM4—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000569	0.00699	CbGpPWpGaD
Paroxetine—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.000563	0.00415	CcSEcCtD
Paroxetine—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.000561	0.00414	CcSEcCtD
Paroxetine—CYP2C8—kidney—nephrolithiasis	0.000559	0.0244	CbGeAlD
Paroxetine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.000558	0.00411	CcSEcCtD
Paroxetine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.000557	0.0041	CcSEcCtD
Paroxetine—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.000553	0.00407	CcSEcCtD
Paroxetine—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000552	0.00678	CbGpPWpGaD
Paroxetine—CHRM3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000551	0.00676	CbGpPWpGaD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000547	0.00671	CbGpPWpGaD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000547	0.00671	CbGpPWpGaD
Paroxetine—CHRM2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000545	0.0067	CbGpPWpGaD
Paroxetine—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.000541	0.00665	CbGpPWpGaD
Paroxetine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.000541	0.00398	CcSEcCtD
Paroxetine—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.000531	0.00391	CcSEcCtD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00053	0.0065	CbGpPWpGaD
Paroxetine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.000523	0.00386	CcSEcCtD
Paroxetine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.000521	0.00384	CcSEcCtD
Paroxetine—CYP2B6—renal system—nephrolithiasis	0.000518	0.0226	CbGeAlD
Paroxetine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.000501	0.00369	CcSEcCtD
Paroxetine—CYP2B6—kidney—nephrolithiasis	0.000501	0.0219	CbGeAlD
Paroxetine—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.000496	0.00365	CcSEcCtD
Paroxetine—Erythema—Hydrochlorothiazide—nephrolithiasis	0.000488	0.0036	CcSEcCtD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000484	0.00595	CbGpPWpGaD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000484	0.00595	CbGpPWpGaD
Paroxetine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000481	0.00355	CcSEcCtD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000481	0.00591	CbGpPWpGaD
Paroxetine—Tension—Hydrochlorothiazide—nephrolithiasis	0.000479	0.00353	CcSEcCtD
Paroxetine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000478	0.00353	CcSEcCtD
Paroxetine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.000474	0.0035	CcSEcCtD
Paroxetine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.000473	0.00348	CcSEcCtD
Paroxetine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00047	0.00346	CcSEcCtD
Paroxetine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00046	0.00339	CcSEcCtD
Paroxetine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.000458	0.00337	CcSEcCtD
Paroxetine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.000453	0.00334	CcSEcCtD
Paroxetine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.000451	0.00333	CcSEcCtD
Paroxetine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.000449	0.00331	CcSEcCtD
Paroxetine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.000446	0.00329	CcSEcCtD
Paroxetine—CHRM5—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000442	0.00543	CbGpPWpGaD
Paroxetine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.000441	0.00325	CcSEcCtD
Paroxetine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.000439	0.00323	CcSEcCtD
Paroxetine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.000438	0.00323	CcSEcCtD
Paroxetine—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.000437	0.00322	CcSEcCtD
Paroxetine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000432	0.00318	CcSEcCtD
Paroxetine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000429	0.00316	CcSEcCtD
Paroxetine—Cough—Hydrochlorothiazide—nephrolithiasis	0.000426	0.00314	CcSEcCtD
Paroxetine—TACR1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000424	0.00521	CbGpPWpGaD
Paroxetine—HTR2A—renal system—nephrolithiasis	0.000423	0.0184	CbGeAlD
Paroxetine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.000416	0.00306	CcSEcCtD
Paroxetine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.000416	0.00306	CcSEcCtD
Paroxetine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000416	0.00306	CcSEcCtD
Paroxetine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.000414	0.00305	CcSEcCtD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000414	0.00509	CbGpPWpGaD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000414	0.00509	CbGpPWpGaD
Paroxetine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.000411	0.00303	CcSEcCtD
Paroxetine—HTR2A—kidney—nephrolithiasis	0.000409	0.0178	CbGeAlD
Paroxetine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000407	0.003	CcSEcCtD
Paroxetine—HTR2A—GPCRs, Other—CHRM3—nephrolithiasis	0.000402	0.00494	CbGpPWpGaD
Paroxetine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000402	0.00296	CcSEcCtD
Paroxetine—CHRM4—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.0004	0.00491	CbGpPWpGaD
Paroxetine—CHRM4—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.0004	0.00491	CbGpPWpGaD
Paroxetine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.000399	0.00294	CcSEcCtD
Paroxetine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.000399	0.00294	CcSEcCtD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000395	0.00485	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Other—CHRM3—nephrolithiasis	0.000395	0.00485	CbGpPWpGaD
Paroxetine—Shock—Hydrochlorothiazide—nephrolithiasis	0.000392	0.00289	CcSEcCtD
Paroxetine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00039	0.00288	CcSEcCtD
Paroxetine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000389	0.00287	CcSEcCtD
Paroxetine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.000385	0.00284	CcSEcCtD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000385	0.00473	CbGpPWpGaD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000385	0.00473	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—RGS14—nephrolithiasis	0.000385	0.00473	CbGpPWpGaD
Paroxetine—CYP2D6—renal system—nephrolithiasis	0.000385	0.0168	CbGeAlD
Paroxetine—CHRM5—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000383	0.00471	CbGpPWpGaD
Paroxetine—CHRM5—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000383	0.00471	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000379	0.00465	CbGpPWpGaD
Paroxetine—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.000373	0.00275	CcSEcCtD
Paroxetine—CYP2D6—kidney—nephrolithiasis	0.000372	0.0162	CbGeAlD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000367	0.00451	CbGpPWpGaD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000367	0.00451	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000366	0.0045	CbGpPWpGaD
Paroxetine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000363	0.00268	CcSEcCtD
Paroxetine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000361	0.00266	CcSEcCtD
Paroxetine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000358	0.00264	CcSEcCtD
Paroxetine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000355	0.00262	CcSEcCtD
Paroxetine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000354	0.00261	CcSEcCtD
Paroxetine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000351	0.00259	CcSEcCtD
Paroxetine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000347	0.00255	CcSEcCtD
Paroxetine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000344	0.00253	CcSEcCtD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000343	0.00422	CbGpPWpGaD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000341	0.00419	CbGpPWpGaD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000341	0.00419	CbGpPWpGaD
Paroxetine—Pain—Hydrochlorothiazide—nephrolithiasis	0.000341	0.00251	CcSEcCtD
Paroxetine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000341	0.00251	CcSEcCtD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000341	0.00419	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000341	0.00419	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—PTH—nephrolithiasis	0.000335	0.00412	CbGpPWpGaD
Paroxetine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000329	0.00242	CcSEcCtD
Paroxetine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000326	0.0024	CcSEcCtD
Paroxetine—CYP2B6—Biological oxidations—SLC26A1—nephrolithiasis	0.00032	0.00393	CbGpPWpGaD
Paroxetine—CHRM5—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000319	0.00392	CbGpPWpGaD
Paroxetine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000317	0.00233	CcSEcCtD
Paroxetine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.000315	0.00232	CcSEcCtD
Paroxetine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000315	0.00232	CcSEcCtD
Paroxetine—HTR2A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000313	0.00384	CbGpPWpGaD
Paroxetine—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000311	0.00382	CbGpPWpGaD
Paroxetine—CHRM3—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00031	0.00381	CbGpPWpGaD
Paroxetine—ABCB1—nephron tubule—nephrolithiasis	0.000305	0.0133	CbGeAlD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000304	0.00374	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000304	0.00373	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000302	0.00371	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000302	0.00371	CbGpPWpGaD
Paroxetine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000294	0.00216	CcSEcCtD
Paroxetine—TACR1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000286	0.00352	CbGpPWpGaD
Paroxetine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000286	0.00211	CcSEcCtD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000286	0.00351	CbGpPWpGaD
Paroxetine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000282	0.00208	CcSEcCtD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00028	0.00344	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000278	0.00342	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000278	0.00341	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000278	0.00341	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000277	0.00341	CbGpPWpGaD
Paroxetine—ABCB1—renal system—nephrolithiasis	0.000277	0.0121	CbGeAlD
Paroxetine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000273	0.00201	CcSEcCtD
Paroxetine—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.000271	0.00333	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00027	0.00331	CbGpPWpGaD
Paroxetine—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00027	0.00331	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000269	0.0033	CbGpPWpGaD
Paroxetine—ABCB1—kidney—nephrolithiasis	0.000268	0.0117	CbGeAlD
Paroxetine—TACR1—Signaling Pathways—ADCY10—nephrolithiasis	0.000268	0.00329	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000266	0.00327	CbGpPWpGaD
Paroxetine—CHRM2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000266	0.00327	CbGpPWpGaD
Paroxetine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000264	0.00194	CcSEcCtD
Paroxetine—ABCB1—cortex of kidney—nephrolithiasis	0.000261	0.0114	CbGeAlD
Paroxetine—TACR1—Signaling by GPCR—DGKH—nephrolithiasis	0.00026	0.00319	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000258	0.00317	CbGpPWpGaD
Paroxetine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000253	0.00187	CcSEcCtD
Paroxetine—Rash—Hydrochlorothiazide—nephrolithiasis	0.000251	0.00185	CcSEcCtD
Paroxetine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000251	0.00185	CcSEcCtD
Paroxetine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00025	0.00184	CcSEcCtD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000247	0.00303	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000246	0.00302	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000246	0.00302	CbGpPWpGaD
Paroxetine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000237	0.00175	CcSEcCtD
Paroxetine—TACR1—Signaling Pathways—RGS14—nephrolithiasis	0.000227	0.00279	CbGpPWpGaD
Paroxetine—HTR2A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000226	0.00278	CbGpPWpGaD
Paroxetine—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000225	0.00276	CbGpPWpGaD
Paroxetine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000222	0.00273	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000221	0.00271	CbGpPWpGaD
Paroxetine—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.000221	0.00271	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000212	0.0026	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000211	0.00259	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000211	0.00259	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000207	0.00254	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000202	0.00248	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000201	0.00247	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000196	0.0024	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000196	0.0024	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—RGS14—nephrolithiasis	0.000195	0.00239	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—PTH—nephrolithiasis	0.000189	0.00233	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000188	0.00231	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000187	0.00229	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000187	0.00229	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—RGS14—nephrolithiasis	0.000186	0.00229	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—RGS14—nephrolithiasis	0.000177	0.00217	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000175	0.00215	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000174	0.00214	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000174	0.00214	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000174	0.00214	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000173	0.00213	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000173	0.00213	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—PTH—nephrolithiasis	0.000172	0.00211	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000172	0.00211	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—RGS14—nephrolithiasis	0.000169	0.00208	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—CHRM3—nephrolithiasis	0.000168	0.00207	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—CHRM3—nephrolithiasis	0.000161	0.00198	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000155	0.0019	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000155	0.0019	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—PTH—nephrolithiasis	0.000154	0.00189	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000154	0.00189	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—DGKH—nephrolithiasis	0.000154	0.00189	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00015	0.00184	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00015	0.00184	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00015	0.00184	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000149	0.00183	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—PTH—nephrolithiasis	0.000147	0.00181	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000147	0.00181	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000139	0.00171	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000134	0.00164	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000132	0.00162	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DGKH—nephrolithiasis	0.000132	0.00162	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000131	0.00161	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—RGS14—nephrolithiasis	0.000131	0.00161	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00013	0.00159	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DGKH—nephrolithiasis	0.000126	0.00155	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000124	0.00152	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ADCY10—nephrolithiasis	0.000123	0.00151	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000122	0.0015	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000122	0.0015	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00012	0.00147	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DGKH—nephrolithiasis	0.000119	0.00147	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.000119	0.00146	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—RGS14—nephrolithiasis	0.000119	0.00146	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—RGS14—nephrolithiasis	0.000118	0.00145	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADCY10—nephrolithiasis	0.000118	0.00144	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DGKH—nephrolithiasis	0.000114	0.0014	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000114	0.0014	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000113	0.00139	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000112	0.00138	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CHRM3—nephrolithiasis	0.000111	0.00136	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RGS14—nephrolithiasis	0.000104	0.00128	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—PTH—nephrolithiasis	0.000104	0.00128	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	0.000104	0.00127	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—PTH—nephrolithiasis	0.000103	0.00127	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—PTH—nephrolithiasis	0.000102	0.00126	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—PTH—nephrolithiasis	0.000102	0.00125	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RGS14—nephrolithiasis	0.0001	0.00123	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CHRM3—nephrolithiasis	9.51e-05	0.00117	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	9.27e-05	0.00114	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	9.27e-05	0.00114	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CHRM3—nephrolithiasis	9.11e-05	0.00112	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DGKH—nephrolithiasis	8.92e-05	0.00109	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	8.87e-05	0.00109	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DGKH—nephrolithiasis	8.84e-05	0.00109	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DGKH—nephrolithiasis	8.75e-05	0.00108	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—PTH—nephrolithiasis	8.7e-05	0.00107	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CHRM3—nephrolithiasis	8.63e-05	0.00106	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	8.62e-05	0.00106	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	8.62e-05	0.00106	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GRHPR—nephrolithiasis	8.4e-05	0.00103	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—PTH—nephrolithiasis	8.33e-05	0.00102	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADCY10—nephrolithiasis	8.33e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	8.28e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CHRM3—nephrolithiasis	8.27e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADCY10—nephrolithiasis	8.26e-05	0.00101	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADCY10—nephrolithiasis	8.18e-05	0.001	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DGKH—nephrolithiasis	8.1e-05	0.000994	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	8.05e-05	0.000989	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DGKH—nephrolithiasis	8.03e-05	0.000986	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DGKH—nephrolithiasis	7.95e-05	0.000976	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PTH—nephrolithiasis	7.9e-05	0.00097	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	7.68e-05	0.000944	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	7.68e-05	0.000944	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PTH—nephrolithiasis	7.56e-05	0.000929	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AGXT—nephrolithiasis	7.48e-05	0.000919	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GRHPR—nephrolithiasis	7.22e-05	0.000887	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RGS14—nephrolithiasis	7.08e-05	0.00087	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DGKH—nephrolithiasis	7.06e-05	0.000866	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ATP6V0A4—nephrolithiasis	7.06e-05	0.000866	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	7.04e-05	0.000865	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RGS14—nephrolithiasis	7.02e-05	0.000862	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RGS14—nephrolithiasis	6.95e-05	0.000854	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.76e-05	0.00083	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DGKH—nephrolithiasis	6.76e-05	0.00083	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CHRM3—nephrolithiasis	6.45e-05	0.000792	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AGXT—nephrolithiasis	6.44e-05	0.000791	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	6.41e-05	0.000787	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—SLC26A1—nephrolithiasis	6.36e-05	0.000781	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—APRT—nephrolithiasis	6.36e-05	0.000781	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CHRM3—nephrolithiasis	6.33e-05	0.000777	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	6.14e-05	0.000754	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GRHPR—nephrolithiasis	6.11e-05	0.000751	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PTH—nephrolithiasis	5.9e-05	0.000724	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	5.86e-05	0.00072	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CHRM3—nephrolithiasis	5.85e-05	0.000719	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PTH—nephrolithiasis	5.85e-05	0.000718	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	5.82e-05	0.000715	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PTH—nephrolithiasis	5.79e-05	0.000711	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CHRM3—nephrolithiasis	5.75e-05	0.000706	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APRT—nephrolithiasis	5.47e-05	0.000672	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—SLC26A1—nephrolithiasis	5.47e-05	0.000672	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AGXT—nephrolithiasis	5.45e-05	0.000669	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PTH—nephrolithiasis	5.35e-05	0.000658	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GRHPR—nephrolithiasis	5.33e-05	0.000654	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	5.33e-05	0.000654	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PTH—nephrolithiasis	5.31e-05	0.000652	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PTH—nephrolithiasis	5.26e-05	0.000646	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CHRM3—nephrolithiasis	5.1e-05	0.000626	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—SPP1—nephrolithiasis	5.1e-05	0.000626	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	5.02e-05	0.000617	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GRHPR—nephrolithiasis	4.98e-05	0.000611	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CHRM3—nephrolithiasis	4.88e-05	0.0006	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.78e-05	0.000587	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DGKH—nephrolithiasis	4.78e-05	0.000587	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.76e-05	0.000584	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	4.76e-05	0.000584	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AGXT—nephrolithiasis	4.75e-05	0.000583	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DGKH—nephrolithiasis	4.74e-05	0.000582	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.74e-05	0.000582	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.7e-05	0.000577	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DGKH—nephrolithiasis	4.7e-05	0.000577	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTH—nephrolithiasis	4.67e-05	0.000573	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	4.63e-05	0.000569	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APRT—nephrolithiasis	4.63e-05	0.000569	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AQP1—nephrolithiasis	4.53e-05	0.000557	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AGXT—nephrolithiasis	4.47e-05	0.00055	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTH—nephrolithiasis	4.47e-05	0.000549	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AGXT—nephrolithiasis	4.44e-05	0.000545	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SLC26A1—nephrolithiasis	4.04e-05	0.000496	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APRT—nephrolithiasis	4.04e-05	0.000496	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AQP1—nephrolithiasis	3.9e-05	0.000479	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	3.8e-05	0.000467	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APRT—nephrolithiasis	3.8e-05	0.000467	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APRT—nephrolithiasis	3.77e-05	0.000463	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	3.77e-05	0.000463	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CHRM3—nephrolithiasis	3.53e-05	0.000433	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CHRM3—nephrolithiasis	3.46e-05	0.000425	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	3.44e-05	0.000422	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CHRM3—nephrolithiasis	3.4e-05	0.000417	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AQP1—nephrolithiasis	3.3e-05	0.000406	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTH—nephrolithiasis	3.16e-05	0.000388	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTH—nephrolithiasis	3.15e-05	0.000386	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTH—nephrolithiasis	3.14e-05	0.000385	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTH—nephrolithiasis	3.11e-05	0.000381	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CHRM3—nephrolithiasis	2.99e-05	0.000367	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AQP1—nephrolithiasis	2.88e-05	0.000353	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AQP1—nephrolithiasis	2.71e-05	0.000333	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AQP1—nephrolithiasis	2.69e-05	0.00033	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CHRM3—nephrolithiasis	2.6e-05	0.00032	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	2.45e-05	0.000301	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CHRM3—nephrolithiasis	2.43e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SPP1—nephrolithiasis	2.34e-05	0.000288	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SPP1—nephrolithiasis	2.24e-05	0.000275	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SPP1—nephrolithiasis	1.59e-05	0.000195	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	1.58e-05	0.000194	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SPP1—nephrolithiasis	1.57e-05	0.000193	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SPP1—nephrolithiasis	1.56e-05	0.000191	CbGpPWpGaD
